1-20 of 59
Erika Hamilton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4151: Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors

Igor Puzanov, Christopher T. Chen, Patricia LoRusso, Kyriakos P. Papadopoulos, Shivaani Kummar, Erika Hamilton, Yvan LeBruchec, Karin Havenith, Serafino Pantano, Marie Toukam, Jens Wuerthner, Joseph Boni
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4151.
DOI: https://doi.org/10.1158/1538-7445.AM2022-4151
Published: 15 June 2022
View article
Journal Articles

Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

Soliman Hatem, Jeffrey Hargis, Anthony Elias, Arielle Lee, Rachel Swart, Shaker Dahkil, Alexandra Drakaki, Vu Phan, Frederic Kass, Melody Cobleigh, Sanil Babu, Katherine Tkaczuk, Brenda O'Connell, Jennifer Roberts, Nora Zizlsperger, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-16-02
Published: 15 February 2022
View article
Journal Articles

Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer

Ming Shan, Laura Spring, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, Steven J Isakoff, James Reeves, Leif W Ellisen, Lee P Lim, Kavita Garg, Caterina Bertucci, Bin Feng, Hailei Zhang, Kaiming Sun, Julie R Graham, Erin Hofstatter, Hyo Han
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-21.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-13-21
Published: 15 February 2022
View article
Journal Articles

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

Timothy A. Yap, Cynthia Basu, Jonathan W. Goldman, Michael Gordon, Erika Hamilton, Adrianne Kelly, Feng Liu, Allison R. Moreau, Heather Neumann, Kyriakos Papadopoulos, Hope S. Rugo, Geoffrey I. Shapiro, Shaveta Vinayak, Li Zhou, Komal Jhaveri
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-16-06
Published: 15 February 2022
View article
Journal Articles

Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

Javier Cortés, Aditya Bardia, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Sara A. Hurvitz, Adam Brufsky, Sagar Sardesai, Kevin M Kalinsky, Tiffany Traina, Erika Hamilton, Joyce O’Shaughnessy, Véronique Diéras, Lisa A. Carey, Martine Piccart, Sibylle Loibl, Hope S. Rugo, Yanni Zhu, See Phan, Luca Gianni
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-15.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-16-15
Published: 15 February 2022
View article
Journal Articles

Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

Erika Hamilton, Linda Vahdat, Hyo S Han, Jennifer Ranciato, Richard Gedrich, Chi F Keung, Deborah Chirnomas, Sara Hurvitz
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD13-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD13-08
Published: 15 February 2022
View article
Journal Articles

Abstract P5-17-05: A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer

Dejan Juric, Phillippe L Bedard, Andrés Cervantes, Valentina Gambardella, Mafalda Oliveira, Cristina Saura, Kevin M Kalinsky, Erika Hamilton, Antoine Italiano, Ian E Krop, Peter Schmid, Nicholas C Turner, Andrea Varga, Stephanie Royer-Joo, Katherine E Hutchinson, Jennifer L Schutzman, Komal L Jhaveri
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-17-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-17-05
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-15-01: SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (ongoing clinical trial)

Alicia Okines, Paula R. Pohlmann, Jorge Ramos, Luke Walker, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-15-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-15-01
Published: 15 February 2022
View article
Journal Articles

Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

Fabrice André, Seock-Ah Im, Patrick Neven, Richard D Baird, Johannes Ettl, Matthew P Goetz, Erika Hamilton, Hiroji Iwata, Zefei Jiang, Anil Abraham Joy, Vincent Haddad, Andrew Walding, Manuel Selvi Miralles, Cynthia Huang Bartlett, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-11-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT2-11-06
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)

Erika Hamilton, Lisa Carey, Jorge Ramos, Yiyi Chen, Ian Krop
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-13-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-13-01
Published: 15 February 2022
View article
Journal Articles

Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs

Erika Hamilton, Thierry Petit, Barbara Pistilli, Anthony Goncalves, Ana Alexandra Ferreira, Florence Dalenc, Fatima Cardoso, Monica M Mita, Luis Manso, Syed M Karim, Francois-Clement Bidard, Philippe Aftimos, Santiago Escriváa-de-Romaníi, Noemia Afonso, Ernesto Wasserman, Kees Bol, Viktoriya Stalbovskaya, Anastasia Vliet, Anastasia Murat, Mohamed Bekradda, Thomas Bachelot
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-15-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT2-15-01
Published: 15 February 2022
View article
Journal Articles

Abstract OT2-14-01: CAPItello-292: A phase Ib/III study of capivasertib, palbociclib and fulvestrant, versus placebo, palbociclib and fulvestrant, for endocrine therapy-resistant HR+/HER2− advanced breast cancer

Hope S Rugo, Gaia Schiavon, Lynda M Grinsted, Elza C De Bruin, Maria Teresa Catanese, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-14-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT2-14-01
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab

Kathy Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-12-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-12-02
Published: 15 February 2022
View article
Journal Articles

Abstract P1-17-12: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

Manish Patel, Carlos Alemany, Zahi Mitri, Della Makower, Virginia Borges, Joseph Sparano, Trinh Le, Pamela Klein, Julia Lawrence, Peter Kushner, Demiana Faltaos, Cyrus Harmon, David Myles, JoAnne Zujewski, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-17-12.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-17-12
Published: 15 February 2022
View article
Journal Articles

Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study

Philippe L Bedard, Seock-Ah Im, Elena Elimova, Sun Young Rha, Rachel Goodwin, Cristiano Ferrario, Keun-Wook Lee, Diana Hanna, Funda Meric-Bernstam, Jose Mayordomo, Murali Beeram, Erika Hamilton, Jorge Chaves, Melody Cobleigh, Tony Mwatha, Joseph Woolery, Do-Youn Oh
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-07
Published: 15 February 2022
View article
Journal Articles

Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer

Ian Krop, Erika Hamilton, Kyung Hae Jung, Shanu Modi, Kevin M Kalinsky, Gail Phillips, Rong Shi, Sharareh Monemi, Michael Mamounas, Ola Saad, Voleak Choeurng, Renee Commerford, Eunpi Cho, Alexander Ungewickell, Patricia LoRusso
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-25.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-25
Published: 15 February 2022
View article
Journal Articles

Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Ian Krop, Dejan Juric, Toshio Shimizu, Anthony Tolcher, Alexander Spira, Toru Mukohara, Aaron E. Lisberg, Takahiro Kogawa, Kyriakos P. Papadopoulos, Erika Hamilton, Senthil Damodaran, Jonathan Greenberg, Wen Gu, Fumiaki Kobayashi, Ferdinand Guevara, Takahiro Jikoh, Yui Kawasaki, Funda Meric-Bernstam, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS1-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS1-05
Published: 15 February 2022
View article
Journal Articles

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sara Hurvitz, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min-Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Javier Cortés
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS3-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS3-01
Published: 15 February 2022
View article
Journal Articles

Abstract LB027: Tracking and decoding the antigen specificity of peripherally derived T cells that infiltrate into solid tumors in patients treated with an autologous T cell therapy, PRIME IL-15 (RPTR-147)

John David Pajerowski, William Gordon, Phil Bardwell, Christine McInnis, Ji Young Hwang, Tabasum Huseni, Parul Agnihotri, Josh Francis, Christina Tarr, Florian Renoux, Sebastian Heer, Nastassja Cerreghetti-Terraneo, Marisa Loi, Erika Hamilton, Sarah Nikiforow, George Blumenschein, Mihaela Christea, Keren Osman, Anthony Shields, Harriet Kluger, Franz-Josef Obermair, Daniel Pregibon, Jan Kisielow, Anthony Coyle, Mojca Skoberne
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB027.
DOI: https://doi.org/10.1158/1538-7445.AM2021-LB027
Published: 01 July 2021
View article
Journal Articles

Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC)

Stephanie Lheureux, Iben Spangaard, Erika Hamilton, George Au-Yeung, Debra Richardson, Mark DeMario, Emily Labriola-Tompkins, Barbara Brennan, Eveline Nueesch, Evelyne Chesne, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB104.
DOI: https://doi.org/10.1158/1538-7445.AM2021-LB104
Published: 01 July 2021
View article